Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Adam Eckert

Why TG Therapeutics Stock Is Plunging Today

TG Therapeutics Inc (NASDAQ:TGTX) shares are trading significantly lower Monday morning after the company announced it has voluntarily withdrawn the pending Biologics License Application/supplemental New Drug Application for the combination of ublituximab and UKONIQ for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

The decision to withdraw the pending applications was based on recently updated overall survival data from the UNITY-CLL Phase 3 trial that showed an increasing imbalance in overall survival.

In addition, TG Therapeutics announced it has voluntarily withdrawn UKONIQ from sale for the approved indications of adult patients. The withdrawal decision was primarily based on the withdrawal of the aforementioned BLA and sNDA.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

See Also: 21 Stocks Moving in Monday's Pre-Market Session

TGTX 52-Week Range: $7.73 - $49.38

According to data from Benzinga Pro, the stock was down 36.7% at $5.60 at time of publication.

Photo: jarmoluk from Pixabay.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.